Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
52 participants
INTERVENTIONAL
2020-03-15
2024-02-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAS1440
TAS1440 as a single agent administered once daily (QD) on specific days during each 28-day cycle in Part 1.
TAS1440
Form: Capsule or Tablet Route of Administration: Oral
TAS1440 + ATRA
TAS1440 administered QD on specific days during each 28-day cycle in combination with ATRA twice daily (BID) in Part 2.
TAS1440 + ATRA
Form: Capsule or Tablet Route of Administration: Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAS1440
Form: Capsule or Tablet Route of Administration: Oral
TAS1440 + ATRA
Form: Capsule or Tablet Route of Administration: Oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Have histological confirmation of AML by World Health Organization (WHO) 2016 criteria and who have failed all other available conventional therapies.
3. Have a peripheral blood or bone marrow blast count \>5% at the time of enrollment.
4. Have disease that:
1. is refractory to standard induction chemotherapy, including but not limited to anthracycline and cytarabine combination therapy, or
2. has relapsed after anthracycline and cytarabine therapy or stem cell transplant (SCT), or
3. is refractory to or has relapsed after a front-line regimen containing a hypomethylating agent, alone or in combination.
5. Have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 1.
6. Have adequate renal function as demonstrated by a serum creatinine ≤1.5 × upper limit of normal (ULN) or calculated creatinine clearance (by the standard Cockcroft-Gault formula) of ≥60 mL/min.
7. Have adequate liver function as demonstrated by the following:
1. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<3 × upper limit of normal (ULN)
2. AST and ALT \<5 × ULN (if considered due to leukemic organ involvement).
8. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group \[CTFG\]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.
Exclusion Criteria
2. BCR-ABL-positive leukemia.
3. Diagnosis of acute promyelocytic leukemia (M3 AML or APML or APL).
4. Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
5. Grade 3 or higher graft versus host disease (GVHD), or GVHD requiring treatment with either:
1. a calcineurin inhibitor, or
2. prednisone more than 5 mg/day (Note: Prednisone at any dose for other indications is allowed).
6. Total serum bilirubin ≥1.5 × ULN (except for subjects with Gilbert's Syndrome for whom direct bilirubin is \>2.5 × ULN), or liver cirrhosis, or chronic liver disease Child-Pugh Class B or C.
7. Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer being treated with antivirals is allowed. For subjects considered at risk of viral exposure, serologies should be used to establish negativity.
8. Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the subject to high risk of non-compliance with the protocol.
9. Myocardial impairment of any cause (eg, cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, or congestive heart failure) resulting in heart failure by New York Heart Association (NYHA) Criteria (Class III or IV staging).
10. Screening 12-lead echocardiogram with measurable QTc interval (according to either Fridericia's or Bazett's correction) of \>480 milliseconds.
11. Active, uncontrolled infection. Participants with an infection receiving treatment (antibiotic, antifungal, or antiviral treatment) must be afebrile and hemodynamically stable for ≥72 hours before enrollment.
12. Non-AML-associated pulmonary disease requiring \>2 liters per minute (LPM) oxygen.
13. Proliferative AML with total white blood cells \> 20,000/uL
14. Any other condition that puts the participant at an imminent risk of death.
15. Treated with any investigational therapy within 2 weeks of the first dose of study treatment.
16. Inability to swallow oral medication.
17. Known hypersensitivity to ATRA, any of its components, or other retinoids.
18. Known sensitivity to parabens.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taiho Oncology, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arizona Cancer Center Site#127
Tucson, Arizona, United States
Norton Cancer Institute Site# 108
Louisville, Kentucky, United States
University of Michigan Medical School Site#107
Ann Arbor, Michigan, United States
Oregon Health and Science University Site#111
Portland, Oregon, United States
Fox Chase Cancer Center Site#112
Philadelphia, Pennsylvania, United States
Baylor Scott & White Research Institute Site#110
Dallas, Texas, United States
MD Anderson Cancer Center Site#101
Houston, Texas, United States
Fred Hutchinson Cancer Research Center Site#105
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAS1440-01
Identifier Type: -
Identifier Source: org_study_id